December 20, 2007
PEARL THERAPEUTICS, INC. EXPANDS ITS SENIOR MANAGEMENT TEAM WITH TOP TALENT IN CLINICAL DEVELOPMENT AND REGULATORY AFFAIRS

December 18, 2007
AMBRX ENTERS FGF-21 TYPE 2 DIABETES DRUG DISCOVERY COLLABORATION WITH MERCK AND CO. INC.

December 17, 2007
AMBRX ANNOUNCES DRUG DISCOVERY ALLIANCE WITH ELI LILLY AND COMPANY

December 12, 2007
PANOMICS INC.: RECIPIENT OF THE FROST & SULLIVAN 2007 UNITED STATES DRUG DISCOVERY TECHNOLOGIES ENTREPRENEURIAL COMPANY OF THE YEAR AWARD

December 11, 2007
ENTREMED ANNOUNCES FDA ACCEPTANCE OF IND APPLICATION FOR PANZEM® IN RHEUMATOID ARTHRITIS

December 10, 2007
ENTREMED PRESENTS RESULTS FOR ITS LEAD AURORA KINASE-ANGIOGENESIS INHIBITOR

November 27, 2007
IKARIA’S INOMAX® (NITRIC OXIDE) FOR INHALATION APPROVED IN AUSTRALIA

November 6, 2007
ENTREMED REPORTS THIRD QUARTER 2007 FINANCIAL RESULTS

November 5, 2007
SYNOSIA THERAPEUTICS ANNOUNCES APPOINTMENT OF VICE PRESIDENT OF CLINICAL RESEARCH AND DEVELOPMENT

October 29, 2007
RELYPSA FORMED WITH $33 MILLION SERIES A FUNDING TO DISCOVER AND DEVELOP POLYMERIC DRUGS

October 25, 2007
ENTREMED SHOWS INCREASED SURVIVAL WITH MKC-1 IN PRECLINICAL RENAL CELL CANCER MODEL

October 25, 2007
ENTREMED REPORTS PHASE 1 PK AND PRECLINICAL EFFICACY RESULTS FOR ENMD-1198

October 24, 2007
ENTREMED PRESENTS RESULTS FOR PANZEM(R) NCD PHASE 2 OVARIAN CANCER STUDY

October 16, 2007
ENTREMED APPOINTS SENIOR VICE PRESIDENT OF RESEARCH AND DEVELOPMENT

October 15, 2007
SYNOSIA THERAPEUTICS ESTABLISHES SCIENTIFIC ADVISORY BOARD

October 1, 2007
IKARIA NAMES EXECUTIVE VICE PRESIDENT OF RESEARCH AND DEVELOPMENT

September 26, 2007
IKARIA FOUNDING SCIENTIST NAMED 2007 MACARTHUR FELLOW

September 25, 2007
NEW STUDY SHOWS PROMISE FOR HYDROGEN SULFIDE IN REDUCING HEART-ATTACK DAMAGE, IKARIA ANNOUNCES

September 19, 2007
SYNOSIA SELECTED AS WINNER OF BIOBUSINESS AWARD

September 10, 2007
ENTREMED PRESENTS DATA FOR PHASE 2 STUDY OF MKC-1 IN METASTATIC BREAST CANCER

September 6, 2007
PEARL THERAPEUTICS RAISES $15.5 MILLION IN PRIVATE FINANCING

July 24 , 2007
AMBRX APPOINTS STEPHEN KALDOR CHIEF EXECUTIVE OFFICER

July 23 , 2007
KALOBIOS RAISES $20 MILLION IN SERIES C FINANCING

June 19 , 2007
MERCK SERONO AND AMBRX TO COLLABORATE ON DEVELOPMENT OF NEXT GENERATION GROWTH HORMONE PRODUCTS

June 11 , 2007
KALOBIOS INITIATES A U.S. PHASE 1 STUDY OF ITS SECOND DRUG CANDIDATE, KB001

June 4 , 2007
AMGEN TO ACQUIRE ILYPSA, A PRIVATE SAN FRANCISCO BAY AREA BIOTECHNOLOGY COMPANY FOCUSED ON KIDNEY DISEASE CARE

May 22 , 2007
NEW AGREEMENT BOOSTS PIPELINE FOR SYNOSIA THERAPEUTICS

May 16 , 2007
SYNOSIA THERAPEUTICS ANNOUNCES APPOINTMENT OF CHIEF MEDICAL OFFICER

May 15 , 2007
MARCADIA BIOTECH COMPLETES $15 MILLION SERIES A FINANCING

APRIL 23 , 2007
KALOBIOS LICENSES HUMANEERING TECHNOLOGY TO MAJOR PHARMACEUTICAL COMPANY

April 23, 2007
SYNOSIA THERAPEUTICS ANNOUNCES SECOND MAJOR PHARMACEUTICAL DEAL

March 28, 2007
IKARIA AND INVESTOR GROUP CLOSE TRANSACTION TO ACQUIRE INO THERAPEUTICS FROM LINDE IN $670 MILLION CASH AND STOCK MERGER, CREATING A WORLD LEADER IN CRITICAL CARE THERAPEUTICS

March 26, 2007
ALEXZA'S AZ-004 PHASE IIa TRIAL PRIMARY ENDPOINT IN TREATING SCHIZOPHRENIC PATIENTS WITH ACUTE AGITATION

March 26, 2007
ALEXZA'S AZ-001 PHASE IIb TRIAL MEETS PRIMARY ENDPOINT OF 2-HOUR PAIN RELIEF IN PATIENTS WITH MIGRAINE HEADACHE

March 14, 2007
ANTHONY TEBBUTT JOINS ALEXZA PHARMACEUTICALS AS SENIOR VICE PRESIDENT, CORPORATE STRATEGY & BUSINESS DEVELOPMENT

March 14, 2007
JEFFREY WILLIAMS NAMED SENIOR VICE PRESIDENT, OPERATIONS & MANUFACTURING AT ALEXZA PHARMACEUTICALS

February 22, 2007
IKARIA AND INVESTOR GROUP TO ACQUIRE INO THERAPEUTICS IN $670 MILLION CASH AND STOCK MERGER

February 12, 2007
AMBRX INITIATES PHASE I/II CLINICAL TRIAL OF NOVEL HUMAN GROWTH HORMONE PRODUCT CANDIDATE

February 8, 2007
ALEXZA UPDATES STATUS OF DEVELOPMENT PIPELINE AND SUMMARIZES 2007 CORPORATE GOALS

February 5, 2007
ANTIPODEAN PHARMACEUTICALS INITIATES PHASE 2 TRIAL IN HEPATITIS C

January 23, 2007
SAFETY MONITORING BOARD RECOMMENDS CONTINUATION OF ENTREMED’S MKC-1 PHASE 2 BREAST CANCER STUDY

January 18, 2007
ALEXZA COMPLETES ENROLLMENT IN AZ-004 PHASE IIA CLINICAL TRIAL IN SCHIZOPHRENIC PATIENTS WITH ACUTE AGITATION

January 4, 2007
VARIATION BIOTECHNOLOGIES SECURES US$35.7 MILLION IN SERIES A FINANCING

January 4, 2007
ROCHE AND SYNOSIS THERAPEUTICS ANNOUNCE PARTNERSHIP